Scientific challenges and implementation barriers to translation of pharmacogenomics in clinical practice.

PubWeight™: 0.98‹?› | Rank: Top 15%

🔗 View Article (PMC 3603526)

Published in ISRN Pharmacol on February 28, 2013

Authors

Y W Francis Lam1

Author Affiliations

1: Department of Pharmacology, School of Medicine, University of Texas Health Science Center San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229-3900, USA.

Associated clinical trials:

Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) Study (PAPI-2) | NCT01452152

Articles cited by this

(truncated to the top 100)

The International HapMap Project. Nature (2003) 73.65

K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 27.35

Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy. JAMA (2003) 14.72

Use of electronic health records in U.S. hospitals. N Engl J Med (2009) 14.36

Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med (2009) 12.63

SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med (2008) 11.31

Clinical assessment incorporating a personal genome. Lancet (2010) 10.18

The path to personalized medicine. N Engl J Med (2010) 9.87

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA (2010) 9.26

Pharmacogenomics: translating functional genomics into rational therapeutics. Science (1999) 8.25

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA (2009) 6.80

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol (2006) 6.55

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA (2010) 6.29

MedEx: a medication information extraction system for clinical narratives. J Am Med Inform Assoc (2010) 6.01

Electronic medical records for genetic research: results of the eMERGE consortium. Sci Transl Med (2011) 5.82

Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther (2011) 5.44

Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N Engl J Med (2011) 5.13

Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol (2010) 5.07

Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther (2008) 4.54

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther (2011) 4.42

Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet (2012) 4.36

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet (2009) 4.32

HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet (2009) 4.11

Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin Pharmacol Ther (2012) 4.05

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol (2009) 4.05

A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med (2011) 3.93

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther (2011) 3.53

Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med (2009) 3.44

Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther (2011) 3.36

A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation (2012) 3.30

Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry (2008) 3.30

A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am J Hum Genet (2008) 3.25

Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther (2012) 3.22

Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther (2012) 3.16

The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther (2012) 3.15

Pharmacogenetic prediction of clozapine response. Lancet (2000) 3.10

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther (2011) 3.09

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood (2010) 2.93

The CE plane: a graphic representation of cost-effectiveness. Med Decis Making (1990) 2.93

The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther (2012) 2.90

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J Clin Oncol (2004) 2.78

A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet (2010) 2.68

Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy (2012) 2.49

Informed consent and subject motivation to participate in a large, population-based genomics study: the Marshfield Clinic Personalized Medicine Research Project. Community Genet (2007) 2.48

Pharmacogenomics: "noninferiority" is sufficient for initial implementation. Clin Pharmacol Ther (2011) 2.43

HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther (2012) 2.36

Predicting clopidogrel response using DNA samples linked to an electronic health record. Clin Pharmacol Ther (2011) 2.36

Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy (2008) 2.34

The MITRE Identification Scrubber Toolkit: design, training, and assessment. Int J Med Inform (2010) 2.29

Anonymization of electronic medical records for validating genome-wide association studies. Proc Natl Acad Sci U S A (2010) 2.24

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer (2008) 2.19

A clinician-driven automated system for integration of pharmacogenetic interpretations into an electronic medical record. Clin Pharmacol Ther (2012) 2.12

Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle intervention in the diabetes prevention program. Diabetes (2010) 2.02

Recommendations from the EGAPP Working Group: testing for cytochrome P450 polymorphisms in adults with nonpsychotic depression treated with selective serotonin reuptake inhibitors. Genet Med (2007) 2.02

Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology (2011) 2.01

CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J (2010) 2.00

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation (2011) 1.99

Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol (2008) 1.93

Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther (2012) 1.88

ACCF/AHA Clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. Circulation (2010) 1.86

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics (2002) 1.85

Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm (2011) 1.85

CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned. J Natl Cancer Inst (2012) 1.81

Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther (2010) 1.77

Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. Pharmacogenomics (2012) 1.66

Concordance of DMET plus genotyping results with those of orthogonal genotyping methods. Clin Pharmacol Ther (2012) 1.62

Assessment of the pharmacogenomics educational needs of pharmacists. Am J Pharm Educ (2011) 1.62

CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand (2001) 1.59

Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education. Pharmacogenomics J (2005) 1.53

A puzzling case of increased serum clozapine levels in a patient with inflammation and infection. Ther Drug Monit (2012) 1.48

ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics (2010) 1.46

Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst (2012) 1.46

Association of pharmacogenetic markers with premature discontinuation of first-line anti-HIV therapy: an observational cohort study. J Infect Dis (2010) 1.45

Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. Mol Psychiatry (2009) 1.44

Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol (2011) 1.43

Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J Clin Pharm Ther (2007) 1.42

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry (2010) 1.39

Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther (2007) 1.35

Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study. Mol Psychiatry (2008) 1.35

D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis. Am J Psychiatry (2010) 1.33

Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support. BMC Bioinformatics (2010) 1.32

Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet (2010) 1.30

Informed lay preferences for delivery of racially varied pharmacogenomics. Genet Med (2003) 1.28

Second-generation antipsychotics: cost-effectiveness, policy options, and political decision making. Psychiatr Serv (2008) 1.27

Survey of US public attitudes toward pharmacogenetic testing. Pharmacogenomics J (2011) 1.27

Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology (2002) 1.23

Clopidogrel: a case for indication-specific pharmacogenetics. Clin Pharmacol Ther (2012) 1.20

Pharmacogenetics of the clozapine response. Lancet (2000) 1.17

Assessing the clinical utility of diagnostics used in drug therapy. Clin Pharmacol Ther (2010) 1.16

Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia. Mol Psychiatry (2008) 1.16

CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol (2000) 1.16

How will GINA influence participation in pharmacogenomics research and clinical testing? Clin Pharmacol Ther (2009) 1.14

PharmGKB and the International Warfarin Pharmacogenetics Consortium: the changing role for pharmacogenomic databases and single-drug pharmacogenetics. Hum Mutat (2008) 1.11

Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry (2009) 1.09

Practical recommendations for pharmacogenomics-based prescription: 2010 ESF-UB Conference on Pharmacogenetics and Pharmacogenomics. Pharmacogenomics (2011) 1.09

Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia. Pharmacogenomics J (2011) 1.08

Epigenomics and interindividual differences in drug response. Clin Pharmacol Ther (2012) 1.07

Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe. Pharmacogenomics (2006) 1.06